151 related articles for article (PubMed ID: 31267008)
21. Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers.
Martell L; Lau K; Mei M; Burnett V; Decker C; Foehr ED
Orphanet J Rare Dis; 2011 Dec; 6():84. PubMed ID: 22176730
[TBL] [Abstract][Full Text] [Related]
22. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic gene transfer to the nervous system using viral vectors.
Glorioso JC; Mata M; Fink DJ
J Neurovirol; 2003 Apr; 9(2):165-72. PubMed ID: 12707847
[TBL] [Abstract][Full Text] [Related]
24. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies.
de Ruijter J; Valstar MJ; Wijburg FA
Curr Pharm Biotechnol; 2011 Jun; 12(6):923-30. PubMed ID: 21235449
[TBL] [Abstract][Full Text] [Related]
25. Therapies for the bone in mucopolysaccharidoses.
Tomatsu S; Alméciga-Díaz CJ; Montaño AM; Yabe H; Tanaka A; Dung VC; Giugliani R; Kubaski F; Mason RW; Yasuda E; Sawamoto K; Mackenzie W; Suzuki Y; Orii KE; Barrera LA; Sly WS; Orii T
Mol Genet Metab; 2015 Feb; 114(2):94-109. PubMed ID: 25537451
[TBL] [Abstract][Full Text] [Related]
26. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
27. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
[TBL] [Abstract][Full Text] [Related]
28. A retrospective audit of anesthetic techniques and complications in children with mucopolysaccharidoses.
Frawley G; Fuenzalida D; Donath S; Yaplito-Lee J; Peters H
Paediatr Anaesth; 2012 Aug; 22(8):737-44. PubMed ID: 22381044
[TBL] [Abstract][Full Text] [Related]
29. [Mucopolysaccharidoses--current aspects of diagnosis and therapy].
Fang-Kircher S
Wien Klin Wochenschr; 1995; 107(22):698-701. PubMed ID: 8533432
[TBL] [Abstract][Full Text] [Related]
30. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
[TBL] [Abstract][Full Text] [Related]
31. Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.
Fillat C; Simonaro CM; Yeyati PL; Abkowitz JL; Haskins ME; Schuchman EH
J Clin Invest; 1996 Jul; 98(2):497-502. PubMed ID: 8755662
[TBL] [Abstract][Full Text] [Related]
32. [Mucopolysaccharidosis: A review].
Michaud M; Belmatoug N; Catros F; Ancellin S; Touati G; Levade T; Gaches F
Rev Med Interne; 2020 Mar; 41(3):180-188. PubMed ID: 31959364
[TBL] [Abstract][Full Text] [Related]
33. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).
Hendriksz CJ
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1521-1532. PubMed ID: 27855521
[TBL] [Abstract][Full Text] [Related]
34. Therapies for neurological disease in the mucopolysaccharidoses.
Anson DS; McIntyre C; Byers S
Curr Gene Ther; 2011 Apr; 11(2):132-43. PubMed ID: 21291356
[TBL] [Abstract][Full Text] [Related]
35. Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.
Sato Y; Okuyama T
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936354
[TBL] [Abstract][Full Text] [Related]
36. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy.
Fecarotta S; Gasperini S; Parenti G
Ital J Pediatr; 2018 Nov; 44(Suppl 2):124. PubMed ID: 30442204
[TBL] [Abstract][Full Text] [Related]
37. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease.
Cearley CN; Wolfe JH
J Neurosci; 2007 Sep; 27(37):9928-40. PubMed ID: 17855607
[TBL] [Abstract][Full Text] [Related]
38. Adeno-associated virus gene transfer in Morquio A disease - effect of promoters and sulfatase-modifying factor 1.
Alméciga-Díaz CJ; Montaño AM; Tomatsu S; Barrera LA
FEBS J; 2010 Sep; 277(17):3608-19. PubMed ID: 20716181
[TBL] [Abstract][Full Text] [Related]
39. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Solano Villarreal ML; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Berger KI; Slasor P; Matousek R; Jurecki E; Shaywitz AJ; Harmatz PR
Mol Genet Metab; 2016 Sep; 119(1-2):131-43. PubMed ID: 27380995
[TBL] [Abstract][Full Text] [Related]
40. Elosulfase alfa.
Haddley K
Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
